NCT00380159View on ClinicalTrials.gov

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions
Human Immunodeficiency Virus (HIV)-1 Infection
Interventions
DRUG

Elvucitabine

Elvucitabine 10 mg in combination with background ART

DRUG

Lamivudine

DRUG

Emtricitabine

Trial Locations (7)

30308

Clinical Trial Site, Atlanta

45242

Clinical Trial Site, Cincinnati

Unknown

Clinical Trial Site, Santo Domingo

Clinical Trial Site, Berlin

Clinical Trial Site, Bonn

Clinical Trial Site, Cologne

Clinical Trial Site, Madrid

Sponsors
All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY